Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non–Small Cell Lung Cancer

Published:2019-03 Issue:2 Volume:21 Page:352-365
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Blidner Richard A.,Haynes Brian C.,Hyter Stephen^ORCID,Schmitt Sarah,Pessetto Ziyan Y.^ORCID,Godwin Andrew K.,Su Dan,Hurban Patrick,van Kempen Léon C.,Aguirre Maria L.,Gokul Shobha,Cardwell Robyn D.,Latham Gary J.

Funder

Cancer Prevention and Research Institute of Texas

National Institute of Environmental Health Sciences

Publisher

Elsevier BV

Subject

Molecular Medicine,Pathology and Forensic Medicine

Reference57 articles.

1. Only three driver gene mutations are required for the development of lung and colorectal cancers;Tomasetti;Proc Natl Acad Sci U S A,2015

2. Lung cancer in never smokers: epidemiology and risk prediction models;McCarthy;Risk Anal,2012

3. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention;Tomasetti;Science,2017

4. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

5. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Analysis of Molecular Testing Methods for FGFR2 Fusion/Rearrangement in Intrahepatic Cholangiocarcinoma;2023-09-29

2. Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non–small cell lung cancer;Cancer;2023-04-25

3. Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision;Cancer Treatment Reviews;2022-11

4. The role of next-generation sequencing in detecting gene fusions with known and unknown partners: a single-center experience with methodologies’ integration;Human Pathology;2022-05

5. Next Generation Sequencing in der Pathologie;Wiener klinisches Magazin;2021-09-24